Nuvilex (NASDAQ:PMCB) Stock Scheduled to Reverse Split on Friday, November 13th

Nuvilex Inc. (NASDAQ:PMCB) shares are going to reverse split on the morning of Friday, November 13th. The 1-19 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, November 12th.

Nuvilex Trading Up 0.8%

Nuvilex stock traded up $0.00 during mid-day trading on Thursday, hitting $0.40. The stock had a trading volume of 398,300 shares, compared to its average volume of 199,711. The stock has a market capitalization of $4.32 million, a PE ratio of -0.17 and a beta of 0.78. The stock has a 50-day simple moving average of $0.40 and a two-hundred day simple moving average of $0.62. Nuvilex has a 12 month low of $0.25 and a 12 month high of $1.51.

Nuvilex (NASDAQ:PMCB) last posted its quarterly earnings results on Monday, September 14th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.48).

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of Nuvilex from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 2nd. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, the stock currently has an average rating of “Sell”.

About Nuvilex

Nuvilex, Inc. was a biotechnology company that later changed its name to PharmaCyte Biotech, Inc. and continued to trade under the ticker symbol PMCB. The company focused on developing cellular therapies intended to treat serious diseases, particularly cancer and diabetes. Its primary technology involved encapsulating genetically engineered human cells in proprietary cellulose-based capsules. These cells were designed to produce therapeutic substances inside the body while limiting exposure to healthy tissue.